Semma Therapeutics appoints Mark Fishman as chairman
Dr. Fishman is currently Professor in the Harvard Department of Stem Cell and Regenerative Biology and Chief of the Pathways Service in Medicine at the MGH.
He served for 13 years as the founding President of the Novartis Institutes for BioMedical Research, appointed in 2002 to devise and implement a new global strategy for Novartis' drug discovery effort.
Before joining Novartis, Dr. Fishman was Chief of Cardiology and founding Director of the Cardiovascular Research Center at Massachusetts General Hospital-
Dr. Fishman was Professor of Medicine at Harvard Medical School where his laboratory discovered many of the genes that drive formation of vertebrate organs, doing so thorough one of the first large scale genetic screens in the zebrafish.
Dr. Fishman completed his internal medicine residency, chief residency and cardiology training at Massachusetts General Hospital.
He graduated with a bachelor’s degree from Yale College in the US in 1972, and with an M.D. from Harvard Medical School in 1976.
Dr. Fishman has been honored with many awards and distinguished lectureships, is a fellow of the American Academy of Arts and Sciences, serves on the council of the National Academy of Medicine. ■
LATEST MOVES FROM Massachusetts
- Chiasma re-appoints Roni Mamluk to board
- BayCoast Bank appoints James Wallace as CFO
- Pulmatrix appoints Amit D. Munshi to board
- Syros Pharmaceuticals appoints Srinivas Akkaraju to board
- Merrimack Pharma names Sergio Santillana as CMO
More inside POST
EasyHotel sales increased 24.7% Earnings